



BLISS GVS PHARMA LIMITED

CIN: L24230MH1984PLC034771

Regd. Office: 102, Hyde Park, Sakivihar Road, Andheri (East), Mumbai - 400 072.

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.09.2014

PART - I

(Rs. in Lacs)

SR. No.	PARTICULARS	STANDALONE					
		QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
		30.09.2014 (UNAUDITED)	30.06.2014 (UNAUDITED)	30.09.2013 (UNAUDITED)	30.09.2014 (UNAUDITED)	30.09.2013 (UNAUDITED)	31.03.2014 (AUDITED)
1	Income From Operations						
	(a) Net Sales (Net of Excise Duty)	8755.69	6980.88	9718.60	15736.57	17090.35	28349.25
	(b) Other Operating Income	173.72	106.11	219.69	279.83	405.61	696.43
	Total Income From Operations (Net)	8929.41	7086.99	9938.29	16016.40	17495.96	29045.68
2	Expenses						
	a) Consumption of Raw Materials	4219.51	2606.90	4,957.68	6,826.41	8,393.96	13,517.82
	b) Purchase of Traded Goods	90.32	0.00	341.43	90.32	500.90	1030.40
	c) Changes in inventories of finished goods, work in progress, Stock in Trade	17.62	268.11	(241.82)	285.73	264.82	60.57
	d) Employee Benefit Expenses	409.13	394.18	335.28	803.31	628.19	1292.61
	e) Depreciation / Amortisation	118.48	112.93	141.57	231.41	246.54	446.16
	f) Other Expenditure	1298.63	1672.76	1686.29	2971.39	3527.57	6314.46
	Total Expenses	6153.69	5054.88	7220.43	11208.57	13561.99	22,662.02
3	Profit From Operations Before Other Income & Finance Cost & Exceptional Items (1-2)	2775.72	2032.11	2717.86	4807.83	3933.98	6383.66
4	Other Income	713.38	249.88	936.78	963.26	2554.34	2789.81
5	Profit From Ordinary Activities Before Finance Cost (3+4)	3489.10	2281.99	3654.64	5771.09	6488.33	9173.47
6	Finance Cost	251.17	223.97	224.63	475.14	413.33	943.63
7	Profit From Ordinary Activities After Finance Cost But Before Exceptional Items (5-6)	3237.93	2058.02	3430.01	5295.95	6074.99	8229.84
8	Exceptional Items	-	-	-	-	-	-
9	Profit From Ordinary Activities Before Tax (7-8)	3237.93	2058.02	3430.01	5295.95	6074.99	8229.84
10	Tax Expense (including Deferred Tax)	1081.20	658.57	1076.67	1739.77	1896.61	2837.19
11	Net Profit After Tax For The Period (9-10)	2156.73	1399.45	2353.34	3556.18	4178.38	5392.65
12	Paid - Up Equity Capital	1031.47	1031.47	1031.47	1031.47	1031.47	1031.47
13	Reserves Excluding Revaluation Reserve (as Per Balance Sheet)	-	-	-	-	-	30452.64
14	Basic And Diluted Eps (Not Annualised)	2.09	1.36	2.28	3.45	4.05	5.23

PART - II

(Rs. in Lacs)

SR. No.	PARTICULARS	STANDALONE					
		QUARTER ENDED			SIX MONTHS ENDED		YEAR ENDED
		30.09.2014 (UNAUDITED)	30.06.2014 (UNAUDITED)	30.09.2013 (UNAUDITED)	30.09.2014 (UNAUDITED)	30.09.2013 (UNAUDITED)	31.03.2014 (AUDITED)
A	Particulars of Shareholding						
1	Aggregate of Non-promoter Shareholding						
	- No. of Shares (Face Value Rs.1/- Each)	36156842	36156842	36156842	36156842	36156842	36156842
	- Percentage of Shareholding (%)	35.05	35.05	35.05	35.05	35.05	35.05
2	Promoter and Promoter Group Shareholding						
	A) Pledge/ Encumbered						
	- No. of Shares (Face Value Re.1/- Each)	-	-	-	-	-	-
	- Percentage of Shares (As % of the total Share Holding of Promoter & Promoter Group)	-	-	-	-	-	-
	- Percentage of Shares (As % of the total Share Capital of The Company)	-	-	-	-	-	-
	B) Non - Encumbered						
	- No. of Shares (Face Value Re.1/- Each)	66989830	66989830	66989830	66989830	66989830	66989830
	- Percentage of Shares (As % of the total Share Holding of Promoter & Promoter Group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (As % of the total Share Capital of The Company)	64.95	64.95	64.95	64.95	64.95	64.95

SR. No.	PARTICULARS	Quarter Ended 30th September 2014	
B	INVESTOR COMPLAINTS		
	Pending at the beginning of the quarter	-	-
	Received during the quarter	2	2
	Disposed off during the quarter	2	2
	REMAINING UNSOLVED AT THE END OF THE QUARTER	-	-

STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2014.

(Rs. in Lacs)

SR. No.	PARTICULARS	STANDALONE	
		Sep - 14	Mar - 14
I.	EQUITY AND LIABILITIES		
1	SHAREHOLDERS' FUNDS :		
	(i) Share Capital	1,031.47	1,031.47
	(ii) Reserves and Surplus	34,236.97	30,452.64
	(iii) Money received against share warrants	-	-
	Sub-total - Shareholders' funds	35,268.44	31,484.11
2	Share Application money pending allotment	-	-
3	Non- Current liabilities		
	(i) Long term Borrowings	3,762.86	4,513.54
	(ii) Deferred tax liabilities (Net)	735.51	619.80
	(iii) Other long term liabilities	-	-
	(iv) Long term provisions	89.70	79.23
	Sub-total - Non-current liabilities	4,588.07	5,212.57
4	Current liabilities		
	(i) Short term Borrowings	2,631.12	2,314.16
	(ii) Trade payables	3,655.91	5,898.97
	(iii) Other current liabilities	3,359.38	2,851.53
	(iv) Short term provisions	1,700.81	878.11
	Sub-total - current liabilities	11,347.22	11,942.77
	Total.....	51,203.73	48,639.45
II.	ASSETS		
1	Non-current assets		
	(a) Fixed Assets	6,441.14	5,783.71
	(b) Non-current Investments	1,922.53	1,922.53
	(c) Deferred tax assets	-	-
	(d) Long term loans and advances	10,716.86	10,617.86
	(e) Other non current assets	92.81	188.66
	Sub-total - Non-current assets	19,173.34	18,512.76
2	Current assets		
	(a) Current Investments	-	-
	(b) Inventories	2,337.61	2,122.89
	(c) Trade receivables	22,347.77	18,353.25
	(d) Cash and Bank balances	5,388.83	7,412.07
	(e) Short term loans and advances	1,098.79	1,552.04
	(f) Other current assets	857.39	686.44
	Sub-total - Current assets	32,030.39	30,126.69
	Total.....	51,203.73	48,639.45

Notes:

- The company operates primarily in the Pharmaceutical Business and hence has only one reportable segment.
- The above results were reviewed by the audit committee & were there after approved by the Board at its meeting held on October 30, 2014
- Pursuant to the Companies Act 2013, becoming effective from April 1, 2014 the Company has computed the depreciation based on the useful life of the assets as prescribed in Schedule II of the Act. This has resulted in additional charge of depreciation of Rs. 59.36 lacs for the half year ended September 30, 2014. Further as per transitional provisions of the Act, the Company has adjusted the written down value of Rs. 4.67 lacs (Net of Deferred Tax of Rs. 2.39 lacs) in respect of assets whose residual life is nil as of April 1, 2014 in the opening balance of retained earnings.
- The statutory auditors have carried out a limited review of the results for the quarter ended September 30, 2014.
- Figures for the previous periods have been regrouped/rearranged wherever necessary.

FOR BLISS GVS PHARMA LIMITED

SD/-

S. N. KAMATH
MANAGING DIRECTOR

Place : Mumbai
Date : 30th October, 2014